Dr Reddy's Laboratories launches Fluphenazine Hydrochloride Tablets, USP in US antipsychotic market
18 February 2021 -

Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE: RDY) on Thursday announced the availability of its antipsychotic medication Fluphenazine Hydrochloride Tablets, USP in the US market.

Fluphenazine Hydrochloride Tablets, USP are a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg and 10 mg, and are approved by the US Food and Drug Administration (FDA).

The Prolixin brand and generic had US sales of approximately USD134m MAT for the 12 months ending in December 2020, according to IQVIA Health.

Fluphenazine is used in the treatment of chronic psychoses such as schizophrenia and psychotic symptoms such as hallucinations, delusions and hostility.